-
1.发明申请PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE 审中-公开药物制剂及其用于预防冲击，糖尿病和/或焦虑性心脏衰竭的药物制剂及其用途公开(公告)号：US20130317047A1
公开(公告)日：2013-11-28
申请号：US13673852
申请日：2012-11-09
发明人： Bernward SCHÔLKENS , Norbert Bender , Badrudin Rangoonwala , Gilles Dagenais , Hertzel Gerstein , Anders Ljunggren , Salim Yusuf
IPC分类号： A61K31/519 , A61K31/41 , A61K31/4184 , A61K31/4178
CPC分类号： A61K31/519 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184
摘要： The present invention relates to use of an inhibitor of the renin-anglotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).
摘要翻译： 本发明涉及肾素 - 血管紧张素系统抑制剂（RAS）或其药学上可接受的衍生物如雷米普利或雷米普利在预防中风，糖尿病和/或充血性心力衰竭（CHF）中的用途。
-
2.发明申请Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof 失效针对肿瘤相关抗原的单克隆抗体（MAb），其制备和应用公开(公告)号：US20090246132A1
公开(公告)日：2009-10-01
申请号：US12068545
申请日：2008-02-07
IPC分类号： A61K51/10 , C07K16/18 , C12N9/00 , A61K39/395 , C07K19/00 , C07K16/46 , C12P21/02 , A61P35/00 , G01N33/53
CPC分类号： C07K16/3084 , A61K38/00 , A61K47/68 , A61K47/6815 , A61K47/6817 , A61K47/6851 , A61K51/1045 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
摘要翻译： 本发明涉及针对肿瘤相关抗原的鼠单克隆抗体（MAb），A，B，C和D。 描述了这些MAb的V基因的几乎完整的核苷酸序列，使得相关的可变结构域可以放在一起以产生嵌合的MAb，或者通过将高变区（互补决定区= CDR）插入到 人类的MAb框架。 这种类型的抗体构建体可以用于人类治疗和体内诊断，而不存在用鼠MAb观察到的缺点。
-
公开(公告)号：US20070213391A1
公开(公告)日：2007-09-13
申请号：US11745131
申请日：2007-05-07
申请人： Ann MINNICH , Theresa KUNTZWEILER , Haifeng EISHINGDRELO , Michael ANGELASTRO , Hans-Jochen LANG
发明人： Ann MINNICH , Theresa KUNTZWEILER , Haifeng EISHINGDRELO , Michael ANGELASTRO , Hans-Jochen LANG
IPC分类号： A61K31/40 , A61K31/341 , C07D207/30 , C07D333/06 , G01N33/50 , C07D307/06 , A61K31/38
CPC分类号： C07D333/20 , C07D207/335 , C07D307/52
摘要： Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:
摘要翻译： 使用表达HM74的宿主细胞获得具有下列结构式的激动剂活性的呋塞米样分子：
-
4.发明申请Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use 有权新型二苯基氮杂环丁酮，其制备方法，包含这些化合物的药物及其用途公开(公告)号：US20070208179A1
公开(公告)日：2007-09-06
申请号：US11797720
申请日：2007-05-07
申请人： Heiner Glombik , Werner Krame , Stefanie Flohr , Wendelin Frick , Hubert Heuer , Gerhard Jaehne , Andreas Lindenschmidt , Hans-Ludwig Schafer
发明人： Heiner Glombik , Werner Krame , Stefanie Flohr , Wendelin Frick , Hubert Heuer , Gerhard Jaehne , Andreas Lindenschmidt , Hans-Ludwig Schafer
IPC分类号： C07D263/20 , C07D205/08
CPC分类号： C07D205/08 , C07F7/1804
摘要： Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
摘要翻译： 其中R1，R2，R3，R4，R5和R6具有说明书中给出的含义的式I化合物及其生理上可接受的盐。 该化合物适合用作例如降血脂药。
-
5.发明授权Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates 失效糖基 - 依托泊苷前药，其制备方法及其与功能化肿瘤特异性酶缀合物的组合公开(公告)号：US07241595B2
公开(公告)日：2007-07-10
申请号：US10128493
申请日：2002-04-24
IPC分类号： C12P19/60
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6815 , A61K47/6851 , A61K47/6899 , A61K2039/505 , C07H17/04 , C07K16/30 , C07K16/3007 , C07K2317/24 , C07K2319/00 , C12N9/16 , C12N9/2434 , C12Y301/03001 , C12Y302/01031
摘要： The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
摘要翻译： 本发明涉及糖基 - 依托泊苷前药，其制备方法及其与用于治疗癌症的官能化肿瘤特异性酶缀合物的组合的用途。
-
公开(公告)号：US06992187B2
公开(公告)日：2006-01-31
申请号：US10363450
申请日：2001-08-29
IPC分类号： C07D473/40 , C07D519/00 , C07D239/49 , C07D401/12
CPC分类号： C07D239/42 , C07D239/48 , C07D401/12 , C07D473/34 , C07D473/40
摘要： A process for the preparation of a compound of the formula wherein the substituents are defined as in the specification.
摘要翻译： 一种制备下式化合物的方法，其中取代基如说明书中所定义。
-
公开(公告)号：US06992067B2
公开(公告)日：2006-01-31
申请号：US10021502
申请日：2001-12-19
申请人： Heiner Glombik , Werner Krame , Stefanie Flohr , Wendelin Frick , Hubert Heuer , Gerhard Jaehne , Andreas Lindenschmidt , Hans-Ludwig Schäfer
发明人： Heiner Glombik , Werner Krame , Stefanie Flohr , Wendelin Frick , Hubert Heuer , Gerhard Jaehne , Andreas Lindenschmidt , Hans-Ludwig Schäfer
IPC分类号： A61K31/70 , A61K31/397 , C07H17/02
CPC分类号： C07D205/08 , C07F7/1804
摘要： Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
-
8.发明申请Method of activating insulin receptor substrate-2 to stimulate insulin production 审中-公开激活胰岛素受体底物-2以刺激胰岛素生成的方法公开(公告)号：US20050250676A1
公开(公告)日：2005-11-10
申请号：US11179972
申请日：2005-07-11
申请人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Jurgen Eckel
发明人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Jurgen Eckel
IPC分类号： A61K38/28
CPC分类号： A61K38/28
摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.
摘要翻译： 本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。 在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用 有效量的Lys B3，Glu B29胰岛素给需要这种治疗的患者。
-
9.发明授权公开(公告)号：US06962943B2
公开(公告)日：2005-11-08
申请号：US10290607
申请日：2002-11-08
申请人： Matthias Schiell , Martin Knauf , Luigi Toti , Astrid Markus-Erb
发明人： Matthias Schiell , Martin Knauf , Luigi Toti , Astrid Markus-Erb
IPC分类号： C07D207/44 , A61K31/40 , C07D207/04 , A01P31/00
CPC分类号： C07D207/44
摘要： The present invention relates to compounds of the formula (I) which are formed by the microorganism ST 003236 (DSM 14476) during fermentation, to a process for preparing and derivatizing them, to a pharmaceutical which comprises a compound of the formula (I) and to the use thereof for producing a pharmaceutical.
摘要翻译： 本发明涉及由发酵过程中的微生物ST-003236（DSM14476）形成的式（I）化合物，其制备方法和衍生化方法，其包含式（I）化合物和 涉及其用于制备药物的用途。
-
10.发明授权公开(公告)号：US06960561B2
公开(公告)日：2005-11-01
申请号：US10102862
申请日：2002-03-22
申请人： Peter Boderke
发明人： Peter Boderke
IPC分类号： A61K9/00 , A61K38/28 , A61K47/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/24 , A61K47/26 , A61K47/28 , A61K47/36 , A61P3/08 , A61P3/10 , A61K31/20 , A61K31/202
CPC分类号： A61K47/18 , A61K9/0019 , A61K38/28 , A61K47/10 , A61K47/26
摘要： The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物和胰岛素衍生物中的至少一种的多肽的制剂; 至少一种表面活性剂; 任选地至少一种防腐剂; 和任选的至少一种等渗剂，缓冲剂或赋形剂，其中所述制剂不含锌或低锌。 本发明还涉及这种胰岛素制剂的生产及其作为药物制剂的用途。
-
-
-
-
-
-
-
-
-
搜索结果
320 条记录 (耗时 0.028 秒)
